



## Reply to: Chronic pain assessment and management during post-treatment follow up should be considered as a high value quality indicator for specialist breast cancer center

We are thankful to Dr. Motiaa Youssef and Dr. Ghannam Abdellilah for referring to our breast cancer 'pattern of care' study in Morocco in their article [1]. While we fully agree with the authors about cancer pain management being an important quality indicator for oncology care, our retrospective study didn't have adequate data on the quality of cancer pain management at the two oncology centers in Morocco. The aim of our study was not to identify and/or validate any indicator for quality of cancer care. We used selected EUSOMA quality Standards that we could report for Morocco based on our retrospective data. It will be a useful initiative to define quality standards for breast cancer care in the Middle East and North Africa (MENA) region.

### References

- [1] Motiaa Y, Ghannam A. Chronic pain assessment and management during post-treatment follow up should be considered as a high value quality indicator for specialist breast cancer center. *The Breast* 2021. <https://doi.org/10.1016/j.breast.2021.09.001>.

Hind Mrabti  
*Institut National d'oncologie, CHU-Rabat, Rabat, Morocco*

Catherine Sauvaget  
*Early Detection, Prevention & Infections Branch, International Agency for Research on Cancer, Lyon, France*

Abdellatif Benider  
*Registre des Cancers de la R\_egion du Grand Casablanca, Casablanca, Morocco*

Karima Bendahhou  
*Registre des Cancers de la R\_egion du Grand Casablanca, Casablanca, Morocco*

Farida Selmouni  
*Early Detection, Prevention & Infections Branch, International Agency for Research on Cancer, Lyon, France*

Richard Muwonge  
*Early Detection, Prevention & Infections Branch, International Agency for Research on Cancer, Lyon, France*

Leila Alaoui  
*National Cancer Institute, Fes, Morocco*

Eric Lucas  
*Early Detection, Prevention & Infections Branch, International Agency for Research on Cancer, Lyon, France*

Youssef Chami  
*Lalla Salma Foundation, Prevention and Treatment of Cancers, Rabat, Morocco*

Patricia Villain  
*Early Detection, Prevention & Infections Branch, International Agency for Research on Cancer, Lyon, France*

Loubna Abousselham  
*Cancer Unit, Epidemiology and Disease Control Department, Ministry of Health, Rabat, Morocco*

Andre L. Carvalho  
*Early Detection, Prevention & Infections Branch, International Agency for Research on Cancer, Lyon, France*

Maria Bennani  
*Lalla Salma Foundation, Prevention and Treatment of Cancers, Rabat, Morocco*

Hassan Errihani  
*Institut National d'oncologie, CHU-Rabat, Rabat, Morocco*

Rengaswamy Sankaranarayanan  
*RTI International India, New Delhi, India*

Rachid Bekkali  
*Lalla Salma Foundation, Prevention and Treatment of Cancers, Rabat, Morocco*

Partha Basu\*  
*Early Detection, Prevention & Infections Branch, International Agency for Research on Cancer, Lyon, France*

\* Corresponding author.  
E-mail address: [basup@iarc.fr](mailto:basup@iarc.fr) (P. Basu).

Available online 6 September 2021

DOIs of original article: <https://doi.org/10.1016/j.breast.2021.07.009>, <https://doi.org/10.1016/j.breast.2021.09.001>.

<https://doi.org/10.1016/j.breast.2021.09.003>

0960-9776/© 2021 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).